Impact of zoledronic acid on control of metastatic spinal cord compression
|
|
- Vivien Dixon
- 6 years ago
- Views:
Transcription
1 Strahlenther Onkol : DOI /s Received: 16 May 2012 Accepted: 30 May 2012 Published online: 18. August 2012 Springer-Verlag 2012 D. Rades 1 S.G. Hakim 2 A. Bajrovic 3 J.H. Karstens 4 T. Veninga 5 V. Rudat 6 S.E. Schild 7 1 Department of Radiation Oncology, University of Lubeck 2 Department of Oral and Maxillofacial Surgery, University of Lubeck 3 Department of Radiation Oncology, University Medical Center Hamburg-Eppendorf 4 Department of Radiation Oncology, Medical University Hannover 5 Department of Radiation Oncology, Dr. Bernard Verbeeten Institute, Tilburg 6 Department of Radiation Oncology, Saad Specialist Hospital Al Khobar 7 Department of Radiation Oncology, Mayo Clinic Scottsdale Impact of zoledronic acid on control of metastatic spinal cord compression About 10 years ago, several randomized trials demonstrated that zoledronic acid was effective in reducing the rate of skeletal-related events in patients with bone metastases [4, 5, 6]. In these trials, skeletal-related events included pathologic fracture, metastatic spinal cord compression (MSCC), radiation therapy to bone, and surgery to bone. However, these outcomes filed under skeletal-related events are rather distinct. MSCC and pathological fractures are complications of bone metastasis, whereas radiotherapy and surgery are treatments that may be given for several indications. Radiotherapy may be administered for MSCC, pathological fractures, pain caused by uncomplicated bone metastases, stabilization of osteolytic lesions to avoid pathological fractures, or prophylactic to avoid MSCC if the vertebral column is involved. Therefore, it appears reasonable to perform studies that focus on a single component of skeletalrelated events. This matched-pair analysis is the first study that particularly examined the effect of zoledronic acid on MSCC, which occurs in up to 14% of all cancer patients during the course of their disease. The present study investigated whether the addition of zoledronic acid to radiotherapy could improve control of MSCC. Material and methods Study design The data of 98 patients treated for MSCC between 2006 and 2011 with radiotherapy and zoledronic acid (Zometa ; Novartis Pharma AG, Basel, Switzerland) were retrospectively analyzed. Each patient treated with radiotherapy plus zoledronic acid was matched with 2 patients from a cohort of 2,212 MSCC patients treated with radiotherapy alone between 1996 and The patients were matched for ten potential prognostic factors: age ( 64 years vs. 65 years; median age 64 years), gender, Eastern Cooperative Oncology Group (ECOG) performance score (ECOG 1 2 vs. ECOG 3 4), type of primary tumor (breast cancer vs. prostate cancer vs. myeloma/lymphoma vs. lung cancer versus other tumors), number of involved vertebrae (1 2 vs. 3), other bone metastases at the time of radiotherapy (no vs. yes), visceral metastases at the time of radiotherapy (no vs. yes), ambulatory status before radiotherapy (not ambulatory vs. ambulatory), time developing motor deficits before radiotherapy (1 7 vs. >7 days), and the radiotherapy regimen (5 fractions of 4 Gy vs. longer-course radiotherapy with 10 fractions of 3 Gy, 15 fractions of 2.5, or 20 fractions of 2 Gy). All of these ten factors should match between the 3 matched patients. Thus, 98 groups of 3 patients met these criteria. These 294 patients had motor deficits due to MSCC of one spinal segment of the thoracic and/or lumbar spine, which had been confirmed by spinal magnetic resonance imaging (MRI). All patients received mg/day of dexamethasone until the end of the radiotherapy course. Patient characteristics related to the two treatment groups are summarized in. Tab. 1. Treatment Radiotherapy was performed with linear accelerators. The treatment volume encompassed one normal vertebra above and below the metastatic lesions. A dose of 4 mg of zoledronic acid adjusted for creatinine clearance was administered intravenously over 15 min in 100 ml of hydration solution (either 0.9% sodium chloride or 5% glucose solution) every 3 4 weeks. Serum creatinine was monitored before each administration. Patients were strongly encouraged to take daily oral supplements of 500 mg calcium and 400 IU vitamin D. Of the 98 receiving zoledronic acid, 15 patients (15%) had received zoledronic acid treatment for median 10 months (range 3 34 months) prior to radiotherapy. In 83 patients (85%) zoledronic acid treat- 910 Strahlentherapie und Onkologie
2 Tab. 1 Distribution of the ten potential prognostic factors in the two treatment groups ment was started during or immediately before radiotherapy. Following radiotherapy, zoledronic acid was given for median 9.5 months (range 1 37 months). Investigated endpoints Patients receiving RT alone n (%) 64 years (n=150) 100 (51) 50 (51) 65 years (n=144) 96 (49) 48 (49) Female (n=204) 136 (69) 68 (69) Male (n=90) 60 (31) 30 (31) 1 2 (n=168) 112 (57) 56 (57) 3 4 (n=126) 84 (43) 42 (43) Breast cancer (n=171) 114 (58) 57 (58) Prostate cancer (n=36) 24 (12) 12 (12) Myeloma/lymphoma (n=24) 16 (8) 8 (8) Lung cancer (n=24) 16 (8) 8 (8) Other tumors (n=39) 26 (13) 13 (13) 1 2 (n=63) 42 (21) 21 (21) 3 (n=231) 154 (79) 77 (79) No (n=48) 32 (16) 16 (16) Yes (n=246) 164 (84) 82 (84) No (n=162) 108 (55) 54 (55) Yes (n=132) 88 (45) 44 (45) Not ambulatory (n=60) 40 (20) 20 (20) Ambulatory (n=234) 156 (80) 78 (80) 1 7 days (n=72) 48 (24) 24 (24) >7 days (n=222) 148 (76) 74 (76) Short-course RT (n=66) 44 (22) 22 (22) Longer-course RT (n=228) 152 (78) 76 (78) RT radiotherapy. Patients receiving RT plus zoledronic acid n (%) Both treatment groups were compared for local control of MSCC (absence of an infield recurrence of MSCC in the irradiated region of the spinal cord), overall control of MSCC (freedom from in-field and out-field recurrences of MSCC), and survival. Recurrence was defined either as recurrence of motor deficits if therapy led to improvement in motor function or as progression of motor deficits if therapy resulted in no change. Because local control of MSCC was a major endpoint of the present study, only patients who experienced improvement or no further progression of motor function were included. The diagnosis of a recurrence of MSCC was confirmed with MRI. Freedom from recurrence and survival were calculated from the last day of radiotherapy. Statistical considerations Local control, overall control and survival rates were calculated with the Kaplan Meier method [1]. The univariate evaluation of the differences between the Kaplan Meier curves was performed with the log-rank test. The prognostic factors found to be significant (p<0.05) or showed a strong trend (p 0.08) in the univariate analysis were included in a multivariate analysis, which was performed with the Cox proportional hazards model. Results All patients were followed until death or for median of 12 months (range 6 39 months) in those alive at the last follow-up visit. The median follow-up in survivors was 12 months (range 6 37 months) in patients receiving zoledronic acid, and 12 months (range 6 39 months) in patients treated with radiotherapy alone. The 1-year local control rate of MSCC was 84% for the entire cohort. The results of the univariate analysis are summarized in. Tab. 2. Radiotherapy plus zoledronic acid resulted in better 1-year local control than radiotherapy alone (90% vs. 81%, p=0.042,. Fig. 1). In addition, improved local control was significantly associated with female gender (p=0.017), favorable type of primary tumor (p=0.002), and longer-course radiotherapy (p=0.006). In the multivariate analysis of local control, the addition of zoledronic acid [relative risk (RR) 2.75; 95% confidence interval (CI) ; p=0.024], and longer-course radiotherapy (RR 2.51; 95% CI ; p=0.022) maintained significance, whereas gender (RR 1.42; 95% CI ; p=0.47) and primary tumor type (RR 1.32; 95% CI ; p=0.10) did not. The 1-year overall control rate of MSCC was 79% for the entire cohort. The results of the univariate analysis of overall control are summarized in. Tab. 3. Radiotherapy plus zoledronic acid resulted in better 1-year overall control than radiotherapy alone (87% vs. 75%, p=0.016,. Fig. 1). In addition to the treatment regimen, improved overall control was significantly associated with female gender (p=0.003) and longer-course radiotherapy (p=0.009). A trend was observed for favorable primary tumor type (p=0.053). In the multivariate analysis, the addition of zoledronic acid (RR 2.74; 95% CI ; p=0.008), and longer- Strahlentherapie und Onkologie
3 course radiotherapy (RR 2.40; 95% CI ; p=0.025) maintained significance. showed a strong trend (RR 2.25; 95% CI ; p=0.054), and primary tumor type was not significant (RR 1.07; 95% CI ; p=0.63). The 1-year survival rate for the entire cohort was 55%. The addition of zoledronic acid did not significantly improve survival at 1 year (60% vs. 52%, p=0.17). On univariate analysis (. Tab. 4), improved survival was associated with age 64 years (p=0.005), female gender (p<0.001), better (p<0.001), favorable tumor type (p<0.001), involvement of only 1 2 vertebrae (p=0.012), absence of visceral metastases (p<0.001), being ambulatory prior to radiotherapy (p<0.001), and a slower development of motor deficits (p<0.001). A trend was observed for absence of other bone metastases (p=0.051). On multivariate analysis, survival was significantly associated with gender (RR 1.64; 95% CI ; p=0.047), visceral metastases (RR 4.41; 95% CI ; p<0.001), ambulatory status (RR 2.06; 95% CI ; p=0.001), and time developing motor deficits (RR 2.47; 95% CI ; p=0.047). Primary tumor type (RR 1.14; 95% CI ; p=0.09), age (RR 1.10; 95% CI: ; p=0.59), ECOG performance status (RR 1.11; 95% CI ; p=0.63), number of involved vertebrae (RR 1.19; 95% CI ; p=0.16), and other bone metastases (RR 1.05; 95% CI ; p=0.88) were not significant in the multivariate analysis of survival. Acute radiotherapy-related toxicity did not exceed grade 1 according to CT- CAE 3.0, and late toxicity such as myelopathy did not occur. Acute grade 3 toxicity rates likely related to zoledronic acid were 1% for hypocalcemia, 1% for anemia, and 1% for serum creatinine increase. Osteonecrosis of the jaw was observed in 4 patients after median 10 months (range 7 13 months) of zoledronic acid treatment. Discussion Zoledronic acid is effective in reducing the rate of skeletal-related events in patients with bone metastases. In 2002, Saad et al. [6] presented a trial of patients Abstract Zusammenfassung Strahlenther Onkol : Springer-Verlag 2012 DOI /s D. Rades S.G. Hakim A. Bajrovic J.H. Karstens T. Veninga V. Rudat S.E. Schild Impact of zoledronic acid on control of metastatic spinal cord compression Abstract Background. Zoledronic acid was demonstrated to reduce the rate of skeletal-related events, a hypernym including various outcomes, in patients with bone metastases. In contrast to other studies, this matched-pair analysis focused solely on the impact of zoledronic acid on metastatic spinal cord compression (MSCC). Patients and methods. Data from 98 patients with MSCC receiving radiotherapy plus zoledronic acid were matched 1:2 to 196 patients receiving radiotherapy alone for ten potential prognostic factors. Both groups were compared for local control of MSCC within the irradiated region, overall control of MSCC (local and distant MSCC control), and survival. Results. The 1-year local control rates were 90% after radiotherapy plus zoledronic acid and 81%, after radiotherapy alone (p=0.042). The 1-year overall control rates were 87% and 75%, respectively (p =0.016), and the 1-year survival rates were 60% and 52%, respectively (p=0.17). Results were significant in the Cox proportional hazards model regarding local control (p=0.024) and overall control (p =0.008). Conclusion. According to the results of this study, zoledronic acid was associated with improved control of MSCC in irradiated patients. Keywords Zoledronic acid Metastatic spinal cord compression Radiotherapy Treatment outcomes Local control Einfluss von Zoledronsäure auf die Kontrolle der metastatisch bedingten Rückenmarkskompression Zusammenfassung Hintergrund. Zoledronsäure verringert die Rate von skelettassoziierten Ereignissen. Unter dem Begriff skelettassoziierte Ereignisse werden verschiedene Endpunkte bei Patienten mit Knochenmetastasen zusammengefasst. Im Gegensatz zu bisherigen Studien konzentriert sich die vorliegende Matched- Pair-Analyse auf den Endpunkt MSCC (metastatisch bedingte Rückenmarkskompression). Patienten und Methode. Im Rahmen einer Matched-Pair-Analyse (1:2) unter Berücksichtigung von 10 möglichen Prognosefaktoren wurden die Daten von 98 Patienten mit einer MSCC, die eine Strahlentherapie plus Zoledronsäure erhielten, mit 196 Patienten, die mit einer alleinigen Strahlentherapie behandelt wurden, verglichen. Untersuchte Endpunkte waren die lokale Kontrolle der MSCC innerhalb der bestrahlten Region, die Gesamt kontrolle der MSCC (innerhalb und außerhalb der bestrahlten Region) und das Gesamtüberleben. Ergebnisse. Die Raten für die lokale Kontrolle betrugen nach einem Jahr 90% nach Strahlentherapie plus Zoledronsäure sowie 81% nach alleiniger Strahlentherapie (p=0,042). Die Raten für die Gesamtkontrolle der MSCC nach einem Jahr betrugen 87% sowie 75% (p=0,016), die Raten für das Gesamtüberleben nach 1 Jahr 60% sowie 52% (p=0,17). Die Unterschiede für die lokale Kontrolle (p=0,024) und die Gesamtkontrolle der MSCC (p=0,008) waren auch in der Multivarianzanalyse signifikant. Schlussfolgerungen. Nach den Ergebnissen dieser Studie verbessert Zoledronsäure die Kontrolle der MSCC nach Strahlentherapie. Schlüsselwörter Zoledronsäure Metastatisch bedingte Rückenmarkskompression Strahlentherapie Behandlungsergebnisse Lokale Kontrolle with hormone-refractory prostate cancer who received either intravenous zoledronic acid at 4 mg (n=214), zoledronic acid at 8 mg subsequently reduced to 4 mg (8 mg/4 mg; n=221), or placebo (n=208) every 3 weeks for 15 months. The rates of skeletal related events were 33%, 39%, and 44%, respectively. The 4 mg regimen was significantly superior to placebo (p=0.021), whereas the 8 mg/4 mg regimen was not (p=0.22). In contrast to the 4 mg regimen, the 8 mg/4 mg regimen was associated with significant impairment of renal function. Therefore, the authors recommended zoledronic acid at 4 mg, which is consistent with the ASCO 912 Strahlentherapie und Onkologie
4 Tab. 2 Univariate analysis of local control of metastatic spinal cord compression (MSCC) At 6 months (%) At 12 months (%) Treatment regimen RT alone (n=196) * RT +zoledronic acid (n=98) years (n=150) years (n=144) Female (n=204) * Male (n=90) (n=168) (n=126) Breast cancer (n=171) * Prostate cancer (n=36) Myeloma/lymphoma (n=24) Lung cancer (n=24) Other tumors (n=39) (n=63) (n=231) No (n=48) Yes (n=246) No (n=162) Yes (n=132) Not ambulatory (n=60) Ambulatory (n=234) days (n=72) >7 days (n=222) Short-course RT (n=66) * Longer-course RT (n=228) *Value considered significantrt radiotherapy. clinical practice guideline update on the role of bone-modifying agents in breast cancer patients [8]. In 2004, Saad et al. [7] presented long-term results of 122 patients who had completed 24 months on study. The rates of skeletal related events were 38% in patients receiving zoledronic acid at 4 mg and 49% in the placebo group, respectively (p=0.028). The annual incidences of skeletal related events were 0.77 in the 4 mg zoledronic acid group and 1.47 in the placebo group, respectively (p=0.005). In 2004, Rosen et al. [4] presented a randomized trial of 773 patients with bone metastases from non-small cell lung cancer or other solid tumors who received either zoledronic acid (4 mg, n=257, or 8 mg/4 mg, n=266) or placebo (n=250) every 3 weeks for 21 months. In the placebo group, the rate of skeletal related events was 46% and higher than with 4 mg (39%; p=0.13) or 8 mg/4 mg of zoledronic acid (36%; p=0.023). In the 4 mg group, the median time to first skeletal related event was delayed when compared to the placebo group (236 vs. 155 days, p=0.009), and the annual incidence was reduced from 2.71 to 1.74 (p=0.012). In 2005, Kohno et al. [2] reported a randomized trial of 228 patients with bone metastases from breast cancer receiving 4 mg zoledronic acid (n=114) or placebo (n=114) every 4 weeks for 12 months. The rates of skeletal related events were 30% and 50%, respectively (p=0.003). A matched-pair analysis following strict matching criteria was performed. Both groups had to match for ten potential prognostic factors. We chose this design in order to control for as many potential sources of bias as possible. Because the data are retrospective in nature, hidden selection biases cannot be entirely excluded. This should be considered when interpreting the results of this study. This matched-pair analysis investigated whether zoledronic acid when added to radiotherapy could to improve control of MSCC in patients irradiated for this complication of bone metastasis. In the trials of Saad et al. [6] and Rosen et al. [4], zoledronic acid did not significantly reduce the rate of MSCC. The rates of MSCC in the trial of Saad et al. [6] were 4% (9/214) in the 4 mg group, 5% (11/221) in the 8 mg/4 mg group, and 7% (14/208) in the placebo group, respectively (p=0.26 for 4 mg vs. placebo; p=0.43 for 8 mg/4 mg vs. placebo). In the trial of Rosen et al. [4], the rates of MSCC were 3% (8/257) in the 4 mg group, 3% (7/266) in the 8 mg/4 mg group, and 4% (10/250) in the placebo group, respectively (not significant). This lack of a significant difference between zoledronic acid and placebo might have been due to the small number of MSCC events in patients with initially uncomplicated bone metastases. In the present study, only patients irradiated for MSCC were included. In a prospective study, the risk of developing a recurrence of MSCC in the irradiated regions of the spinal cord was 29% at 1 year [3]. If one includes the recurrences of MSCC outside the irradiated regions, this rate is higher. Therefore, a greater number of MSCC events could be expected in the present study when compared to the trials of Saad et al. [6] and Rosen et al. [4], leading to a greater probability of achieving a significant difference when comparing patients treated with radiotherapy alone to those who received radiotherapy plus zoledronic acid. And indeed, according to the findings of the present study, the addition of zoledronic acid to radiotherapy improved Strahlentherapie und Onkologie
5 P=0.042 RT + ZOL RT alone time to local recurrence (months) 8. Van Poznak CH, Temin S, Yee GC et al (2011) American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29: P=0.016 RT + ZOL RT alone time to any recurrence (months) Fig. 1 9 Comparison of radiotherapy plus zoledronic acid (RT+ZOL) to radiotherapy alone (RT alone) with respect to local control and overall control of MSCC local control and overall control of MSCC in patients irradiated for this complication of bone metastasis. Corresponding address D. Rades, M.D. Department of Radiation Oncology, University of Lubeck Ratzeburger Allee 160, Lubeck Germany Rades.Dirk@gmx.net Conflict of interest. On behalf of all authors, the corresponding author states the following: DR: study grant (Novartis Oncology), speaker s honoraria (Amgen). References 1. Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53: Kohno N, Aogi K, Minami H et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23: Rades D, Lange M, Veninga T et al (2011) Final results of a prospective study comparing the local control of short-course and long-course radiotherapy for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 79: Rosen LS, Gordon DH, Dugan W et al (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100: Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase II, double-blind, randomized trial The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21: Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94: Saad F, Gleason DM, Murray R et al (2004) Longterm efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: Strahlentherapie und Onkologie
6 Tab. 3 Univariate analysis of overall control of metastatic spinal cord compression (MSCC) At 6 months (%) At 12 months (%) p Treatment regimen RT alone (n=196) * RT +zoledronic acid (n=98) years (n=150) years (n=144) Female (n=204) * Male (n=90) (n=168) (n=126) Breast cancer (n=171) Prostate cancer (n=36) Myeloma/lymphoma (n=24) Lung cancer (n=24) Other tumors (n=39) (n=63) (n=231) No (n=48) Yes (n=246) No (n=162) Yes (n=132) Not ambulatory (n=60) Ambulatory (n=234) days (n=72) >7 days (n=222) Short-course RT (n=66) * Longer-course RT (n=228) *Value considered significantrt radiotherapy. Strahlentherapie und Onkologie
7 Tab. 4 Univariate analysis of survival At 6 months (%) At 12 months (%) p Treatment regimen RT alone (n=196) RT +zoledronic acid (n=98) years (n=150) * 65 years (n=144) Female (n=204) <0.001* Male (n=90) (n=168) <0.001* 3 4 (n=126) Breast cancer (n=171) <0.001* Prostate cancer (n=36) Myeloma/lymphoma (n=24) Lung cancer (n=24) Other tumors (n=39) (n=63) * 3 (n=231) No (n=48) Yes (n=246) No (n=162) <0.001 Yes (n=132) Not ambulatory (n=60) <0.001* Ambulatory (n=234) days (n=72) <0.001* >7 days (n=222) Short-course RT (n=66) Longer-course RT (n=228) *Value considered significantrt radiotherapy. 916 Strahlentherapie und Onkologie
A new score predicting the survival of patients with spinal cord compression from myeloma
Douglas et al. BMC Cancer 2012, 12:425 RESEARCH ARTICLE Open Access A new score predicting the survival of patients with spinal cord compression from myeloma Sarah Douglas 1, Steven E Schild 2 and Dirk
More informationA new instrument for estimation of survival in elderly patients irradiated for metastatic spinal cord compression from breast cancer
Rades et al. Radiation Oncology (2015) 10:173 DOI 10.1186/s13014-015-0483-8 RESEARCH A new instrument for estimation of survival in elderly patients irradiated for metastatic spinal cord compression from
More informationRipamonti C, et al. ASCO 2012 (Abstract 9005)
ZOOM: A Prospective, Randomized Trial of Zoledronic Acid for Long-term Treatment in Patients With Bone-Metastatic Breast Cancer After 1 Year of Standard Zoledronic Acid Treatment D. Amadori, M. Aglietta,
More informationBone Metastases and Osteoporosis
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Bone Metastases and Osteoporosis Bone Metastases Version 2002: Dall / Fersis / Friedrich Version 2003 2009: Bischoff / Böhme
More informationThe management and treatment options for secondary bone disease. Omi Parikh July 2013
The management and treatment options for secondary bone disease Omi Parikh July 2013 Learning Objectives: The assessment and diagnostic process of patients with suspected bone metastases e.g bone scan,
More informationCastrate-resistant prostate cancer: Bone-targeted agents. Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Castrate-resistant prostate cancer: Bone-targeted agents Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for: Amgen, Astellas,
More informationEfficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data
Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data Richard Bell The Andrew Love Cancer Centre Cancer Services, Medical Oncology, Geelong, Victoria, Australia Key Words. Bisphosphonate
More informationElderly men with prostate cancer + ADT
Elderly men with prostate cancer + ADT Background and Rationale ADT and Osteoporosis Proportion of Patients With Fractures 1-5 Yrs After Cancer Diagnosis 21 18 +6.8%; P
More informationBone Metastases. Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital
Bone Metastases Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital 1 Outline Pathophysiology Signs & Symptoms Diagnosis Treatment Spinal Cord Compression 2 General Information
More informationEfficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with Advanced Cancer
Review Articles Jpn J Clin Oncol 2012;42(8)663 669 doi:10.1093/jjco/hys088 Advance Access Publication 13 June 2012 Efficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with
More informationACR Appropriateness Criteria Metastatic Epidural Spinal Cord Compression and Recurrent Spinal Metastasis EVIDENCE TABLE
. Cole JS, Patchell RA. Metastatic epidural spinal cord compression. Lancet Neurol. 2008;7(5):59-66. 2. Loblaw DA, Mitera G, Ford M, Laperriere NJ. A 20 updated systematic review and clinical practice
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 11 April 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 11 April 2012 XGEVA 120 mg, solution for injection 1 glass vial of 120 mg/1.7 ml (CIP code: 217 253-8) 4 glass vials
More informationHOW I DO IT. Introduction. BARKIN J. How I Do It: Managing bone health in patients with prostate cancer. Can J Urol 2014;21(4):
HOW I DO IT How I Do It: Managing bone health in patients with prostate cancer Jack Barkin, MD Department of Surgery, University of Toronto, Humber River Hospital, Toronto, Ontario, Canada BARKIN J. How
More informationSurvival and prognostic factors in patients with stable and unstable spinal bone metastases from solid tumors: a retrospective analysis of 915 cases
Wolf et al. BMC Cancer (2016) 16:528 DOI 10.1186/s12885-016-2571-z RESEARCH ARTICLE Open Access Survival and prognostic factors in patients with stable and unstable spinal bone metastases from solid tumors:
More informationManagement of Metastatic Bone Pain: Preliminary Results with Single Fraction (4 Gy) Radiotherapy
Short Communication Kurzmittei Onkologie 989;:44 Management of Metastatic Bone Pain: Preliminary Results with Single Fraction (4 Gy) Radiotherapy J.H. Karstens B. Schnabel J. Ammon Klinik für Strahlentherapie,
More informationRadiotherapy for Patients with Symptomatic Intramedullary Spinal Cord Metastasis
J. Radiat. Res., 52, 641 645 (2011) Regular Paper Radiotherapy for Patients with Symptomatic Intramedullary Spinal Cord Metastasis Haruko HASHII 1,4 *, Masashi MIZUMOTO 1,4 *, Ayae KANEMOTO 1,4, Hideyuki
More informationIdentification of the Risk Factors of Bone Metastatic among Breast Cancer Women in Al-Bashir Hospital
Advances in Breast Cancer Research, 2018, 7, 120-129 http://www.scirp.org/journal/abcr ISSN Online: 2168-1597 ISSN Print: 2168-1589 Identification of the Risk Factors of Bone Metastatic among Breast Cancer
More informationAvailable online at ScienceDirect. EJSO 41 (2015) 1691e1698
Available online at www.sciencedirect.com ScienceDirect EJSO 41 (2015) 1691e1698 www.ejso.com Posterior decompression and spine stabilization for metastatic spinal cord compression in the cervical spine.
More informationHigh-precision radiotherapy of motor deficits due to metastatic spinal cord compression (PRE-MODE): a multicenter phase 2 study
Rades et al. BMC Cancer (2017) 17:818 DOI 10.1186/s12885-017-3844-x STUDY PROTOCOL High-precision radiotherapy of motor deficits due to metastatic spinal cord compression (PRE-MODE): a multicenter phase
More informationBone Health in Patients with Multiple Myeloma
Bone Health in Patients with Multiple Myeloma Amrita Y. Krishnan, MD Director Judy and Bernard Briskin Myeloma Center City of Hope Comprehensive Cancer Center Bone Health Bisphosphonates in Space Bone
More informationThe Latest is the Greatest. Future Directions in the Management of Patients with Bone Metastases from Breast Cancer
City Wide Medical Oncology Rounds Friday Sept. 21 st, 2007 The Latest is the Greatest Future Directions in the Management of Patients with Bone Metastases from Breast Cancer Mark Clemons Head, Breast Medical
More informationBisphosphonates in the Management of. Myeloma Bone Disease
Bisphosphonates in the Management of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Myeloma Bone Disease Myeloma cells
More informationBone metastases of solid tumors Diagnosis and management by
Bone metastases of solid tumors Diagnosis and management by Dr/RASHA M Abd el Motagaly oncology consultant Nasser institute adult oncology unit 3/27/2010 1 Goals 1- Know the multitude of problem of bone
More informationRadiotherapy symptoms control in bone mets. Francesco Cellini GemelliART. Ernesto Maranzano,MD. Session 5: Symptoms management
Session 5: Symptoms management Radiotherapy symptoms control in bone mets Francesco Cellini GemelliART Ernesto Maranzano,MD Director of Oncology Department Chief of Radiation Oncology Centre S. Maria Hospital
More informationEvaluation of prognostic scoring systems for bone metastases using single center data
MOLECULAR AND CLINICAL ONCOLOGY 3: 1361-1370, 2015 Evaluation of prognostic scoring systems for bone metastases using single center data HIROFUMI SHIMADA 1, TAKAO SETOGUCHI 2, SHUNSUKE NAKAMURA 1, MASAHIRO
More informationA prediction model of survival for patients with bone metastasis from uterine corpus cancer
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2016, 46(11) 973 978 doi: 10.1093/jjco/hyw120 Advance Access Publication Date: 21 September 2016 Original Article Original
More informationGUIDELINES ON THE USE OF BISPHOSPHONATES IN PALLIATIVE CARE. November 2007(Amended July 2008)
Yorkshire Palliative Medicine Clinical Guidelines Group GUIDELINES ON THE USE OF BISPHOSPHONATES IN PALLIATIVE CARE November 2007(Amended July 2008) Authors: Dr Kath Lambert and Dr Liz Brown, on behalf
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Zoledronic acid Therapeutic Area of Trial Breast cancer, prostrate cancer Approved Indication Prevention of skeletal related events
More informationManagement of Bone Metastasis in Breast Cancer: Drugs, Dosing and Duration
Management of Bone Metastasis in Breast Cancer: Drugs, Dosing and Duration Kara Laing, MD, FRCPC Chair and Associate Professor, Discipline of Oncology Memorial University of Newfoundland Medical Oncologist,
More informationDepartment of Orthopedic Surgery, Henan Province People s Hospital, Henan, People s Republic of China; 2
Int J Clin Exp Med 2018;11(3):2465-2470 www.ijcem.com /ISSN:1940-5901/IJCEM0060812 Original Article Validation of a scoring system predicting survival and function outcome in patients with metastatic epidural
More informationManaging Skeletal Metastases
Managing Skeletal Metastases Alison Stopeck, M.D. Professor of Medicine Director, Breast Cancer Program University of Arizona Cancer Center Tucson, AZ Disclosures: Consulting, research funding, and honoraria
More informationQuando e qual o momento de iniciar os Bifosfonatos no Câncer de Próstata
Quando e qual o momento de iniciar os Bifosfonatos no Câncer de Próstata Igor A. Protzner Morbeck, MD, MSc Professor de Medicina Universidade Católica de Brasília Oncologista Clínico Onco-Vida Brasília-DF
More informationWe have previously reported good clinical results
J Neurosurg 113:48 52, 2010 Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional
More informationClinical Case Conference
Clinical Case Conference Palliative radiation therapy for bone metastasis Jeff Burkeen, MD, PGY2 7/20/2015 1 Overview Epidemiology Pathophysiology Common presentations and symptoms Imaging Surgery Radiation
More informationDENOSUMAB. . Peter Harper Guy s, King s & St Thomas & Leaders in Oncology Care (LOC) DENOSUMAB. RANK-L/Bisphosphonates; Bone secondaries & Lung Cancer
DENOSUMAB. Peter Harper Guy s, King s & St Thomas & Leaders in Oncology Care (LOC) DENOSUMAB RANK-L/Bisphosphonates; Bone secondaries & Lung Cancer. Peter Harper Guy s, King s & St Thomas & Leaders in
More informationThe management and treatment options for secondary bone disease. Dr Jason Lester Clinical Oncologist Velindre Cancer Centre
The management and treatment options for secondary bone disease Dr Jason Lester Clinical Oncologist Velindre Cancer Centre Aims Overview of bone metastases management in castrate-refractory prostate cancer
More informationOncologist. The. Academia Pharma Intersect: Symptom Management and Supportive Care
The Oncologist Academia Pharma Intersect: Symptom Management and Supportive Care Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases MATTI AAPRO, a FRED SAAD, b LUIS
More informationSpinal cord compression as a first presentation of cancer: A case report
J Pain Manage 2013;6(4):319-322 ISSN: 1939-5914 Nova Science Publishers, Inc. Spinal cord compression as a first presentation of cancer: A case report Nicholas Lao, BMSc(C), Michael Poon, MD(C), Marko
More informationSource of effectiveness data The effectiveness evidence was derived from a single study that was identified from a review of the literature.
Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK Guest J F, Clegg J P, Davie A M, McCloskey E Record Status This is a critical
More informationThe use of surgery in the elderly. for management of metastatic epidural spinal cord compression
The use of surgery in the elderly Bone Tumor Simulators for management of metastatic epidural spinal cord compression Justin E. Bird, M.D. Assistant Professor Orthopaedic Oncology and Spine Surgery Epidemiology
More informationAmgen (Europe) GmbH, Zug, Switzerland, 2 Amgen GmbH, Munich, Germany, 3
Occurrence of skeletal-related events (SRE) in pa9ents with solid tumors (ST): early versus late ini9a9on of SRE preventa9ve agents (SPA) Intorcia M 1, Hohmann D 2, Giannopoulou C 1, Ansorge S 3, Diel
More informationProduct: Denosumab (AMG 162) Abbreviated Clinical Study Report: (Extension Phase Results) Date: 24 August 2010 Page Page 2 of 2 of
Product: Denosumab (MG 162) bbreviated Clinical Study Report: 20040114 (Extension Phase Results) Date: 24 ugust 2010 Page Page 2 of 2 of 1314 55 2. SYNOPSIS Name of Sponsor: mgen Inc. Name of Finished
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationZoledronic Acid Is Superior to Pamidronate for the Treatment of Bone Metastases in Breast Carcinoma Patients with at Least One Osteolytic Lesion
36 Zoledronic Acid Is Superior to Pamidronate for the Treatment of Bone Metastases in Breast Carcinoma Patients with at Least One Osteolytic Lesion Lee S. Rosen, M.D. 1 David H. Gordon, M.D. 2 William
More informationMalignant Spinal cord Compression. Dr. Thiru Thirukkumaran Palliative Care Services - Northwest Tasmania
Malignant Spinal cord Compression Dr. Thiru Thirukkumaran Palliative Care Services - Northwest Tasmania Background Statistics of SCC -1 Incidence of SCC Vertebral body metastases 85 % Para-vertebral (Lymphoma)
More informationTreatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer
Treatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer Nobukazu Fuwa 1, Akinori Takada 2 and Takahiro Kato 3 1;Departments of Radiology, Hyogo Ion Beam Medical
More informationFREQUENTLY ASKED QUESTIONS
FREQUENTLY ASKED QUESTIONS The following questions are representative of questions that patients and family members ask when they visit the Bone and Cancer Foundation website or contact the Foundation
More informationMetastatic Spinal Disease
Metastatic Spinal Disease Mr Neil Chiverton Consultant Spinal Surgeon, Sheffield Objectives The scale and nature of the problem NICE recommendations Surgical decision making Case illustrations Incidence
More informationManagement of Acute Oncological emergencies
Management of Acute Oncological emergencies Malignant Spinal cord compression (MSCC) Neutropenic sepsis Superior vena caval obstruction Hypercalcemia Hyponatremia Bowel obstruction Brain Metastasis with
More informationKey Words. Biologic markers Breast neoplasms Survival rate Zoledronic acid
The Oncologist Breast Cancer Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity ALLAN LIPTON, a RICHARD J. COOK, b PIERRE MAJOR, c MATTHEW
More informationMetastatic spinal cord compression (MSCC) is one
SPINE Volume 41, Number 18, pp 1469 1476 ß 2016 Wolters Kluwer Health, Inc. All rights reserved SURGERY Who are the Best Candidates for Decompressive Surgery and Spine Stabilization in Patients With Metastatic
More informationSurvival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery
ORIGINAL ARTICLE Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery Ann C. Raldow, BS,* Veronica L. Chiang, MD,w Jonathan P.
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationCase Conference: SBRT for spinal metastases D A N I E L S I M P S O N M D 3 / 2 7 / 1 2
Case Conference: SBRT for spinal metastases D A N I E L S I M P S O N M D 3 / 2 7 / 1 2 Case 79 yo M with hx of T3N0 colon cancer diagnosed in 2008 metastatic liver disease s/p liver segmentectomy 2009
More informationApproved SYNOPSIS. Product: Denosumab (AMG 162) Interim Synopsis Clinical Study Report: Date: 23 July 2010.
Page 2 of 24012 SYNOPSIS Name of Sponsor: Amgen Inc Name of Finished Product: not applicable Name of Active Ingredient: denosumab (AMG 162) Title of Study: A Randomized, Double-Blind, Multicenter Study
More informationProphylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer
Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer Dr Neil Bayman Consultant Clinical Oncology ESMO-Christie Preceptorship Programme in Lung Cancer, March
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationMalignant epidural spinal cord compression: the role of external beam radiotherapy
REVIEW C URRENT OPINION Malignant epidural spinal cord compression: the role of external beam radiotherapy Tanya Holt a, Peter Hoskin b, Ernesto Maranzano c, Arjun Sahgal d, Steven E. Schild e, Samuel
More informationCurrent Management of Metastatic Bone Disease
Current Management of Metastatic Bone Disease Evaluation and Medical Management Dr. Sara Rask Head, Medical Oncology Simcoe Muskoka Regional Cancer Centre www.rvh.on.ca Objectives 1. Outline an initial
More informationA prospective study of patients with impending spinal cord compression treated with palliative radiotherapy alone
A prospective study of patients with impending spinal cord compression treated with palliative radiotherapy alone Item Type Article Authors O'Sullian, L.;Clayton-Lea, A.;McArdle, O.;McGarry, M.;Kenny,
More informationAn exploration on the radiological features associated with motor deficits in patients with
European Review for Medical and Pharmacological Sciences An exploration on the radiological features associated with motor deficits in patients with metastatic epidural spinal cord compression Y.-S. LIU,
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationRecognition & Treatment of Malignant Spinal Cord Compression Study Day
Recognition & Treatment of Malignant Spinal Cord Compression Study Day 11 th May 2017 Dr Bernie Foran Consultant Clinical Oncologist & Honorary Senior Lecturer Weston Park Hospital Outline of Talk Clinical
More informationBone Metastases. Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. AGO e. V. in der DGGG e.v. sowie in der DKG e.v.
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Bone Metastases Bone Metastases Version 2002: Dall / Fersis / Friedrich Versions 2003 2011: Bischoff / Böhme / Brunnert / Diel
More informationPalliative treatments for lung cancer: What can the oncologist do?
Palliative treatments for lung cancer: What can the oncologist do? Neil Bayman Consultant Clinical Oncologist GM Cancer Palliative Care and Lung Cancer Education Event Manchester, 31 st January 2017 Most
More informationAdvanced Prostate Cancer. SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin
Advanced Prostate Cancer SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin aurelius.omlin@kssg.ch Conflicts of Interest Research Support: TEVA, Janssen Advisory Rolle: Astra Zeneca, Astellas,
More informationPublished Ahead of Print on May 2, 2009 as /theoncologist
The Oncologist Symptom Management and Supportive Care High Incidence of Hypocalcemia and Serum Creatinine Increase in Patients with Bone Metastases Treated with Zoledronic Acid MONICA ZURADELLI, a GIOVANNA
More informationKey Words. Breast cancer Elderly Metastatic
The Oncologist Breast Cancer Use of Intravenous Bisphosphonates in Older Women with Breast Cancer SHARON H. GIORDANO, a SHENYING FANG, a ZHIGANG DUAN, b YONG-FANG KUO, c GABRIEL N. HORTOBAGYI, a JAMES
More informationManaging Skeletal Metastases
School of Breast Oncology 2012 Managing Skeletal Metastases Cathy Van Poznak, MD Assistant Professor University of Michigan Comprehensive Cancer Center Saturday, November 3, 2012 Learning Objectives: Define
More informationa Phase II Randomised Controlled Trial Matthias Guckenberger
Dose-intensified Image-guided Fractionated Stereotactic Body Radiation Therapy for Painful Spinal Metastases (DOSIS) versus Conventional Radiation Therapy: a Phase II Randomised Controlled Matthias Guckenberger
More informationSYNOPSIS PROTOCOL N UC-0107/1602
SYNOPSIS PROTOCOL N UC-0107/1602 A) TRIAL IDENTIFICATION SPONSOR PROTOCOL CODE NUMBER: UC-0107/1602 VERSION (NR & DATE): 0.1, MARCH 2016 TRIAL TITLE: Extracranial Stereotactic Body Radiation Therapy (SBRT)
More informationClinical Study Survival Prediction Score: A Simple but Age-Dependent Method Predicting Prognosis in Patients Undergoing Palliative Radiotherapy
ISRN Oncology, Article ID 912865, 5 pages http://dx.doi.org/10.1155/2014/912865 Clinical Study Survival Prediction Score: A Simple but Age-Dependent Method Predicting Prognosis in Patients Undergoing Palliative
More informationScottish Medicines Consortium
Scottish Medicines Consortium zoledronic acid 5mg/100ml solution for infusion (Aclasta) No. (317/06) Novartis 8 September 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationPalliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased
Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased analysis Roel Schlijper Fellow Radiation Oncology BC Cancer, Prince George Disclosures No conflicts
More informationTHERAPEUTIC EFFICACY AND PHARMACOECONOMICS EVAULATION OF PAMIDRONATE VERSUS ZOLEDRONIC ACID IN MULTIPLE MYELOMA PATIENTS
438 J App Pharm 04(03): 438-452 (2011) Qasim et al., 2011 ORIGINAL ARTICLE THERAPEUTIC EFFICACY AND PHARMACOECONOMICS EVAULATION OF PAMIDRONATE VERSUS ZOLEDRONIC ACID IN MULTIPLE MYELOMA PATIENTS Saima
More informationIsotopes and Palliative Radiotherapy for bone metastases
Isotopes and Palliative Radiotherapy for bone metastases Rationale for Bone-seeking Isotope Therapies in Prostate Cancer > 90% of patients with advanced prostate cancer have bone metastases which can be
More informationKey words: Bisphosphonates, guidelines, drug use evaluation, breast cancer
DO PHYSICIA FOLLOW SYSTEMIC TREATMENT AND FUNDING POLICY GUIDELINES? A REVIEW OF BISPHOSPHONATE USE IN PATIENTS WITH BONE METASTASES FROM BREAST CANCER Mark Clemons 1, Katherine Enright 1, Annemarie Cesta
More informationDepartment of Oncology and Palliative Medicine, Nordland Hospital, 8092 Bodø, Norway 2
The Scientific World Journal Volume 212, Article ID 69323, 5 pages doi:1.11/212/69323 The cientificworldjournal Clinical Study Towards Improved Prognostic Scores Predicting Survival in Patients with Brain
More informationFIBROBLAST GROWTH FACTOR 2 A PREDICTOR OF OUTCOME FOR PATIENTS IRRADIATED FOR STAGE II-III NON SMALL-CELL LUNG CANCER
doi:10.1016/j.ijrobp.2010.08.048 Int. J. Radiation Oncology Biol. Phys., Vol. 82, No. 1, pp. 442 447, 2012 Copyright Ó 2012 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ - see front
More informationACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS.
ACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS. ÁLVARO PINTO Servicio de Oncología Médica Hospital Universitario La Paz IdiPAZ, Madrid INTRODUCTION High
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationCommunity care of Prostate Cancer. Shaun Costello Southern Cancer Network
Community care of Prostate Cancer Shaun Costello Southern Cancer Network Introduction Why is GP follow up of prostate cancer important 4Years In Waikato Faster Cancer Treatment Reporting against the 3
More informationsymposium article introduction symposium article
Annals of Oncology 17 (Supplement 5): v118 v122, 2006 doi:10.1093/annonc/mdj965 Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/ vinblastine/doxorubicin/cisplatin
More informationKombination von Checkpointinhibitoren beim malignen Melanom
Kombination von Checkpointinhibitoren beim malignen Melanom Dirk Jäger Medizinische Onkologie Nationales Centrum für Tumorerkrankungen Universitätsklinikum Heidelberg Ipilimumab beim metastasierten Melanom
More informationSecond Single 4 Gy Reirradiation for Painful Bone Metastasis
26 Journal of Pain and Symptom Management Vol. 23 No. 1 January 2002 Original Article Second Single 4 Gy Reirradiation for Painful Bone Metastasis Branislav Jeremic, MD, PhD, Yuta Shibamoto, MD, DMSc,
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More informationPredicting the survival of patients with bone metastases treated with radiation therapy: a validation study of the Katagiri scoring system
Kubota et al. Radiation Oncology (2019) 14:13 https://doi.org/10.1186/s13014-019-1218-z RESEARCH Predicting the survival of patients with bone metastases treated with radiation therapy: a validation study
More informationNeues zur neoadjuvanten Vorbehandlung beim Rektumkarzinom
Neues zur neoadjuvanten Vorbehandlung beim Rektumkarzinom Prof. Dr. med. R. Fietkau Strahlenklinik Disclosure I have the following potential confilct(s) of interest to report: Type of affiliation/ financial
More informationA Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma Fred Saad, Donald M. Gleason, Robin Murray, Simon Tchekmedyian, Peter Venner,
More informationMetastatic Spinal Cord Compression
Metastatic Spinal Cord Compression Dr Zacharias Tasigiannopoulos Clinical Oncologist Colney centre Department of Oncology Norwich, UK Introduction 2-5% of cancer patients have an episode of MSCC Initial
More informationA Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,
More informationManaging Bone Pain in Metastatic Disease. Rachel Schacht PA-C Medical Oncology and Hematology Associates Presented on 11/2/2018
Managing Bone Pain in Metastatic Disease Rachel Schacht PA-C Medical Oncology and Hematology Associates Presented on 11/2/2018 None Disclosures Managing Bone Pain in Metastatic Disease This lecture will
More informationCON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer
CON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute Emory University
More informationSummary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, Nasdaq: DNDN
Summary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, 2009 Nasdaq: DNDN PROVENGE sipuleucel-t is an autologous active cellular immunotherapy that activates
More informationIbandronate: Its Role in Metastatic Breast Cancer
Ibandronate: Its Role in Metastatic Breast Cancer David Cameron, a Marie Fallon, a Ingo Diel b a Western General Hospital, Edinburgh, United Kingdom; b Institute for Gynecological Oncology, Mannheim, Germany
More informationBone Health in the Cancer Patient. Stavroula Otis, M.D. Primary Care and Oncology: Practical Lessons Conference Brea Community Center May 10, 2018
Bone Health in the Cancer Patient Stavroula Otis, M.D. Primary Care and Oncology: Practical Lessons Conference Brea Community Center May 10, 2018 Overview Healthy bone is in a constant state of remodelling
More informationZoledronic acid in the management of metastatic bone disease
REVIEW Zoledronic acid in the management of metastatic bone disease Thomas J Polascik Vladimir Mouraviev Duke Prostate Center and Division of Urologic Surgery, Duke University Medical Center, Durham, NC,
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
More informationGUIDELINES FOR RADIOTHERAPY IN SPINAL CORD COMPRESSION THE CHRISTIE, GREATER MANCHESTER & CHESHIRE. Version:
GUIDELINES FOR RADIOTHERAPY IN SPINAL CORD COMPRESSION THE CHRISTIE, GREATER MANCHESTER & CHESHIRE Procedure Reference: Document Owner: Dr V. Misra Version: Accountable Committee: V4 Acute Oncology Group
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More information